Health Catalyst
Health Catalyst's revenue rose 1.5% to $311 million in fiscal 2025. Its operating margin was −51.7%, down from −22.8% a year earlier. Free cash flow was −$0 million, against $13 million a year earlier. It paid out $5 million in dividends and buybacks. The diluted share count rose 16.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Health Catalyst does
Health Catalyst sells data and analytics software and services to healthcare organizations, mostly hospitals and health systems in the United States. Its cloud platform, Ignite, pulls together data from a client's many separate computer systems. Software applications built on top of it help clients study and improve patient care, revenue and costs, clinic operations and quality reporting.
It reports two segments, technology and professional services. The services include analytics work, advice from experts, training, and running some of a client's operations for it. The company says more than 90% of its revenue recurs, mainly through subscriptions, and its larger platform contracts often run three to five years. At the end of 2025 it served 162 platform clients and over 1,000 clients that use only its applications. It competes with companies that it says include large, well-funded technology firms.
At the end of 2025 Health Catalyst had more than 1,200 team members, most of them in the United States and about 16% in India. It is moving clients from its older platform to Ignite, a change it says has led some to cut back or leave.
Its biggest risks, as it describes them
- Tough competition, including from larger rivals with more money and closer ties to health systems.
- Clients not renewing, renewing for less, or cutting back services, including during the move to Ignite.
- Relying on a few large clients for a big share of its revenue.
- Changes in the healthcare industry and its rules that could reduce demand for its products.
- Its reliance on Microsoft Azure and on outside data sources to run its platform.
Income statement
Health Catalyst lost money in fiscal 2025: a net loss of $178 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 445 | 364 | 318 | 392 | 96 |
| Debt incl. finance leases | 181 | 226 | 228 | 382 | 153 |
| Net debt (negative means net cash) | −264 | −137 | −90 | −10 | 58 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.5x | 0.6x | 1.1x | 0.6x |
| Interest coverage | −22.6x | −24.4x | −22.1x | −6.9x | −7.3x |
| Current ratio | 5.5x | 5.2x | 4.4x | 1.4x | 1.9x |
| Quick ratio | 5.5x | 5.2x | 4.4x | 1.4x | 1.9x |
Cash flow
Projections
Project Health Catalyst's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Health Catalyst says to expect
- Full year 2026: total revenue and adjusted EBITDA
For the full year of 2026, we expect: • Total revenue of $246 million to $249 million, and • Adjusted EBITDA of $18 million to $18.5 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $105,610 of Health Catalyst shares on the open market, and 2 insiders sold $200,554, $72,402 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Simeon KohlChief Executive Officer, Director | Bought | 59,000 | $1.79 | $105,610 | Form 4 |
| Dec 5, 2025 | Benjamin LandryGeneral Counsel | Sold plan | 27,425 | $2.64 | $72,402 | Form 4 |
| Dec 4, 2025 | Julie Larson-GreenDirector | Sold | 47,997 | $2.67 | $128,152 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 4 of 8 |
| Rule of 40 | −4.5% | 7.8% | 1.4% |
| Altman Z'' | −2.41 | −3.21 | −8.96 |
| Accruals ratio | −11.7% | −10.8% | −26.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 3 of 8 | 4 of 8 | 4 of 8 |
Compare
Put Health Catalyst side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Health Catalyst | FY25 | 1.5% | −51.7% | −0.1% | −38.6% | — | 4 | |
| HealthStream | FY25 | 4.3% | 6.7% | 19.6% | — | — | — | Compare |
| Omada Health | FY25 | 53.2% | −4.6% | 6.5% | — | — | — | Compare |
| Amwell | FY25 | −2.0% | −42.2% | −26.5% | — | — | — | Compare |
| Certara | FY25 | 8.8% | 5.0% | 22.6% | 0.9% | 1.1x | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 73 | 113 | 155 | 189 | 242 | 276 | 296 | 307 | 311 |
| Revenue growth | — | 54.0% | 37.6% | 21.9% | 28.1% | 14.2% | 7.1% | 3.6% | 1.5% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 28 | 39 | 46 | 54 | 63 | 76 | 73 | 58 | 50 |
| Operating income | −46 | −60 | −55 | −96 | −144 | −140 | −127 | −70 | −161 |
| Net income | −47 | −62 | −60 | −115 | −153 | −137 | −118 | −70 | −178 |
| Diluted EPS (US$) | −12.13 | −23.76 | −12.86 | −2.91 | −3.23 | −2.63 | −2.09 | −1.15 | −2.55 |
| Diluted shares (millions) | 5 | 5 | 19 | 40 | 48 | 54 | 56 | 60 | 70 |
| Cash flow | |||||||||
| Cash from operations | −37 | −40 | −32 | −26 | −23 | −35 | −33 | 15 | 1 |
| Capital expenditure | 2 | 2 | 2 | 8 | 10 | 2 | 1 | 2 | 1 |
| Free cash flow | −39 | −42 | −34 | −34 | −34 | −37 | −34 | 13 | −0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 9 | 0 | 0 | 0 | 8 | 2 | 0 | 5 |
| Acquisitions | 0 | 0 | 0 | 102 | 47 | 28 | 11 | 80 | 41 |
| Stock-based compensation | 4 | 4 | 18 | 38 | 65 | 72 | 56 | 40 | 27 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 23 | 33 | 228 | 271 | 445 | 364 | 318 | 392 | 96 |
| Debt incl. finance leases | — | 20 | 48 | 169 | 181 | 226 | 228 | 382 | 153 |
| Total assets | — | 111 | 302 | 578 | 832 | 752 | 702 | 859 | 503 |
| Total liabilities | — | 76 | 102 | 302 | 310 | 327 | 335 | 494 | 257 |
| Shareholders' equity | −260 | −375 | 201 | 276 | 522 | 425 | 367 | 365 | 246 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | −62.3% | −53.4% | −35.4% | −50.9% | −59.4% | −50.7% | −42.9% | −22.8% | −51.7% |
| Net margin | −64.4% | −55.1% | −38.8% | −60.9% | −63.3% | −49.7% | −39.9% | −22.7% | −57.2% |
| Free cash flow margin | −53.8% | −37.6% | −22.1% | −18.0% | −13.9% | −13.6% | −11.6% | 4.2% | −0.1% |
| Rule of 40 (growth + FCF margin) | — | 16.4% | 15.6% | 3.9% | 14.2% | 0.6% | −4.5% | 7.8% | 1.4% |
| Return on capital | — | — | — | −78.0% | −52.5% | −40.5% | −35.5% | −17.4% | −38.6% |
| Return on equity | — | — | — | −48.2% | −38.4% | −29.0% | −29.8% | −19.0% | −58.3% |
| Return on assets | — | — | −29.1% | −26.1% | −21.7% | −17.3% | −16.2% | −8.9% | −26.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |